Related Experiment Video
Updated: May 21, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Benchmarking benzodiazepines and antipsychotics in the last 24 hours of life
1Mary Potter Hospice, PO Box 7442, Wellington South, New Zealand. brian.ensor@marypotter.org.nz
Aims:
To document benzodiazepines and antipsychotics (BDZ/APS) given to patients in the last 24 hours of life to establish normal prescribing patterns in hospices across New Zealand (NZ).
Methods:
A cross-sectional benchmarking design with retrospective chart review was carried out across 14 NZ hospices. Data (n=351) on medication use and dosages was analysed for inter-hospice variability. Analysis was shared with participating hospices for reflection.
Results:
There are significant differences in how these predominantly sedative medications are used within hospices in NZ, though the reasons for this cannot be commented on in this study. Diagnosis, place of death and use of the Liverpool Care Pathway influence how medications are used.
Conclusion:
NZ hospices are willing to submit data to enable the description of usual medication use in NZ, and have established that variations in prescribing and administration exist. This enables self reflection on the variations and the establishment of an ongoing benchmarking exercise.
Related Concept Videos
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Pharmacodynamics in Geriatric Patients: Effects of Age
Anxiolytic Drugs: Benzodiazepines and Buspirone
Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
